Table 2.
Top 20 FDA-approved drugs that positively modulate HbF in iRBCs (CD45+ cells derived from sickle-cell patients that have been in vitro differentiated towards an erythroid lineage).
| Drug Name | Fold Change | Indication |
|---|---|---|
| Daunorubicin Hydrochloride | 5.76 | Acute Myeloid Leukemia |
| Perphenazine | 5.16 | Schizophrenia |
| Acyclovir | 5.14 | Viral Infection |
| Cefazolin Sodium | 4.71 | Bacterial Infection |
| Epirubicin Hydrochloride | 4.59 | Breast Cancer |
| Atenolol | 4.49 | Hypertension |
| Methoxsalen | 4.44 | Cutaneous T-Cell Lymphoma |
| Ampiroxicam | 4.34 | Arthritis |
| Prednisolone | 4.32 | Rheumatoid Arthritis |
| Oxytetracycline hydrochloride | 4.30 | Bacterial Infection |
| Pfizerpen | 4.14 | Bacterial Infection |
| Tetracycline | 3.95 | Bacterial Infection |
| Pitavastatin | 3.92 | Elevated Cholesterol |
| Benazepril Hydrochloride | 3.80 | Elevated Blood Pressure |
| Triamcinolone Acetonide | 3.67 | Eczema |
| Phenelzine | 3.52 | Depression |
| Digoxin | 3.50 | Heart Failure |
| Dibenzyline | 3.28 | Pheochromocytoma |
| Buspar | 3.28 | Anxiety |
| Fluoxetine Hydrochloride | 3.25 | Depression |